SITE008-0022

SITE008 (KOR) › SITE008-0022

SITE008-0022

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE008 (KOR) · Dr. Kim
consented 2025-09-12

enrolled

AEs

6

Serious

0

Dropout signal

–

Adverse events

6

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-02-23 (study day 334); relationship: NOT RELATED

mild assessed

Grade 2 Vomiting — outcome: RECOVERED/RESOLVED; onset 2023-01-06 (study day 286); relationship: not assessed

moderate assessed

Grade 2 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2022-09-16 (study day 174); relationship: not assessed

moderate assessed

Grade 1 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2022-09-12 (study day 170); relationship: NOT RELATED

mild assessed

Grade 3 Fatigue — outcome: RECOVERED/RESOLVED; onset 2022-07-18 (study day 114); relationship: NOT RELATED

severe assessed

Grade 2 Vomiting — outcome: RECOVERED/RESOLVED; onset 2022-06-24 (study day 90); relationship: NOT RELATED

moderate assessed

Data queries

0

No data queries. Open queries would appear here for this patient.